Takara Bio Inc. (TYO:4974)

Market Cap	137.51B +49.7%
Revenue (ttm)	44.15B +2.5%
Net Income	-7.20B
EPS	-59.79
Shares Out	120.42M
PE Ratio	n/a
Forward PE	n/a
Dividend	17.00 (1.49%)
Ex-Dividend Date	n/a

Volume	86,300
Average Volume	489,285
Open	1,142.00
Previous Close	1,142.00
Day's Range	1,142.00 - 1,143.00
52-Week Range	752.00 - 1,150.00
Beta	0.44
RSI	63.51
Earnings Date	May 13, 2026

About Takara Bio

Takara Bio Inc., together with its subsidiaries, engages in the businesses of reagents, equipment, contract services, and genetic medicine in Japan, China, the rest of Asia, the United States, Europe, and internationally. The company sells reagents and instruments, including reagents needed for genetic and cellular research, PCR instruments, cellular analysis devices, and in vitro diagnostics for COVID-19 testing. It also provides contract services related to regenerative medicine products and contract services related to gene analysis and test...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 1,779
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4974

Financial Performance

In fiscal year 2025, Takara Bio's revenue was 45.04 billion, an increase of 3.53% compared to the previous year's 43.51 billion. Earnings were 1.04 billion, a decrease of -29.66%.